Member Info for Wilson63

Pv72 I can read it off my iPhone if any help

S20 Tks posting safestocks which has the part of the note which I'm most interested in, whatever people think of posters being positive/negative read the stifel opinion and decide who you believe.

Pm

"We are now well positioned to continue executing our strategy, build cash reserves, and progress a range of options to meet our convertible note obligations in October 2026."

:))))

RG increasing holding is great news perhaps he hasn't stopped and the 3.5 mil buy at 1707 belongs to him, strange time for anyone to sell currently .

I didn't even comment on the Rns R as I thought it was precisely that, good comms by the company ahead of next week and that would be that lol.

Bit of a bummer as I've started "dry" January, breaking it after one day I'll get dogs abuseHappy New Year all.

Impressive 30 out of 76 posts are green boxes.

Thanks to RAH on X

https://www.ddw-online.com/phase-i-trial-shows-90-disease-control-in-salivary-gland-cancers-39642-202512/

CC said Tremendous in the Rns .

"These data are key to support the clinical development of FAP-Exd (AVA6103) and the profile of this second pre|CISION medicine in the preclinical setting is tremendous. The sustained release mechanism developed by Avacta scientists results in a robust concentration of active drug in the tumor over five days with the disappearance from the bloodstream in only two hours. This is the exact profile needed to achieve better efficacy with this highly potent topo I inhibitor."

What does tremendous mean?

Merry Christmas all.

For context

Christina Coughlin

@coughlin582

·

5h

We are delighted to bring the pharmacology updates and the latest data in the FAP-Exd program at #AVCT . This one looking quite good in the preclinical setting. Trial is ready to go and detailed here

Fredd1eboy, read the 29th August Rns, seemingly a lot of confidence by RH that money could/can be raised by a few different options.

Fap is hotting up certainly

Absolutely whole of this post accredited to stonks on X

https://www.mdpi.com/2379-139x/11/12/143

Avacta mention is section 8

novel FAP-activated prodrug of doxorubicin, named AVA6000, has demonstrated selective activation within the TME, which significantly reduces systemic toxicity while maintaining antitumor efficacy in FAP-rich models, and is currently in phase I clinical trials with an expected completion date in 2026 [226,227

Good read actually as I say all laid on a plate by stonks on X many Tks to that poster.

And lo and behold the meeting is currently down(I have read it) odds on it being slightly different when it reappears.

Two more in santas green sack. This board is unreadable the majority of the time.

Hopefully dot the i's cross the T's and launch, Merry Christmas incoming.

CC posting last half hour

"Delighted to share a great conversation about #AVCT with Tom Weir on the Biohub podcast Ep 97. An exciting time for Avacta is on the horizon!"

My two takes

1. Japanese, doesn't matter size it's the break through , amazing how some cherry pick what they comment on.

2. From Rns

As the July 2026 deadline for camera-based DMS in Europe approaches, it is our expectation that many current Automotive programs will be extended and potentially expanded to incorporate additional features."

Does for me.

They are green boxes to me couldn't you just report them when they lie, as it appears they often do, I'd imagine people with helpful information may post it on here.

P.s I only know they lie as people often post the lie they are responding to.

Courtesy of stonks on x

https://www.labiotech.eu/in-depth/dual-payload-adcs-pdcs/

You will sleep tonight s20

And for those that don't know Royal Buek(6months before my first buy)

https://www.proactiveinvestors.com/companies/news/54013/update-seeing-machines-has-ideal-partner-in-royal-beuk-64034.html